Innate Pharma: Clinical events update from conference call

 ...On September 23rd, we are pleased to announce that we will be presenting preliminary data from the mycosis fungoides cohort 2 in a few weeks at the EORTC Congress in Madrid. On Slide 7, let me summarize the progress we are making with the care now. We are pursuing a fast-to-market strategy for lacutamab in the NIS study of Sézary syndrome where lacutamab was granted U.S. Fast Track designation and EU prime designation in 2020. We have expanded past Sézary syndrome to mycosis fungoides, where we have seen encouraging preliminary data from our Phase II trial. For Sézary syndrome and mycosis fungoides enrollment is on track. For Sézary syndrome, we will be presenting the initial data from the potentially pivotal cohort in the second half of 2022. 

https://finance.yahoo.com/news/edited-transcript-iph-pa-earnings-120000100.html